Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M, 2017. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.  Oncotarget 8(5):7598-7613

Leoni C; Montagner S; Rinaldi A; Bertoni F; Polletti S; Balestrieri C; Monticelli S, 2017. Dnmt3a restrains mast cell inflammatory responses.  Proc Natl Acad Sci U S A 114(8):E1490-E1499

Bujisic B; De Gassart A; Tallant R; Demaria O; Zaffalon L; Chelbi S; Gilliet M; Bertoni F; Martinon F, 2017. Impaired IRE1 expression and XBP1 activation is a hallmark of GCB-DLBCL and contributes to tumor growth.  Blood.

Zucca E; Bertoni F, 2016. The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance.  Blood 127(17):2082-92

Groner AC; Cato L; de Tribolet-Hardy J; Bernasocchi T; Janouskova H; Melchers D; Houtman R; Cato AC; Tschopp P; Gu L; Corsinotti A; Zhong Q; Fankhauser C; Fritz C; Poyet C; Wagner U; Guo T; Aebersold R; Garraway LA; Wild PJ; Theurillat JP; Brown M, 2016. TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer.  Cancer Cell 29(6):846-58

Bernasconi E; Gaudio E; Kwee I; Bertoni F, 2016. Assessment of the Antiproliferative Activity of a BET Bromodomain Inhibitor as Single Agent and in Combination in Non-Hodgkin Lymphoma Cell Lines.  Methods Mol Biol 1436:305-12

Gaudio E; Tarantelli C; Kwee I; Barassi C; Bernasconi E; Rinaldi A; Ponzoni M; Cascione L; Targa A; Stathis A; Goodstal S; Zucca E; Bertoni F, 2016. Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.  Ann Oncol 27(6):1123-8

Civenni G; Longoni N; Costales P; Dallavalle C; García Inclán C; Albino D; Nuñez LE; Morís F; Carbone GM; Catapano CV, 2016. EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB.  Mol Cancer Ther 15(5):806-18

Di Mitri D; Alimonti A, 2016. Non-Cell-Autonomous Regulation of Cellular Senescence in Cancer.  Trends Cell Biol 26(3):215-26

Pizzi M; Boi M; Bertoni F; Inghirami G, 2016. Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.  Leukemia 30(9):1805-15

Delaleu N; Mydel P; Brun JG; Jonsson MV; Alimonti A; Jonsson R, 2016. Sjögren's syndrome patients with ectopic germinal centers present with a distinct salivary proteome.  Rheumatology (Oxford) 55(6):1127-37

Albino D; Civenni G; Dallavalle C; Roos M; Jahns H; Curti L; Rossi S; Pinton S; D'Ambrosio G; Sessa F; Hall J; Catapano CV; Carbone GM, 2016. Activation of the Lin28/let-7 Axis by Loss of ESE3/EHF Promotes a Tumorigenic and Stem-like Phenotype in Prostate Cancer.  Cancer Res 76(12):3629-43

Matic I; Revandkar A; Chen J; Bisio A; Dall'Acqua S; Cocetta V; Brun P; Mancino G; Milanese M; Mattei M; Montopoli M; Alimonti A, 2016. Identification of Salvia haenkei as gerosuppressant agent by using an integrated senescence-screening assay.  Aging (Albany NY) 8(12):3223-3240

Revandkar A; Perciato ML; Toso A; Alajati A; Chen J; Gerber H; Dimitrov M; Rinaldi A; Delaleu N; Pasquini E; D'Antuono R; Pinton S; Losa M; Gnetti L; Arribas A; Fraering P; Bertoni F; Nepveu A; Alimonti A, 2016. Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence.  Nat Commun 7:13719

Gomes AL; Teijeiro A; Burén S; Tummala KS; Yilmaz M; Waisman A; Theurillat JP; Perna C; Djouder N, 2016. Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular Carcinoma.  Cancer Cell 30(1):161-75

Boi M; Todaro M; Vurchio V; Yang SN; Moon J; Kwee I; Rinaldi A; Pan H; Crescenzo R; Cheng M; Cerchietti L; Elemento O; Riveiro ME; Cvitkovic E; Bertoni F; Inghirami G, 2016. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.  Oncotarget 7(48):79637-79653

Riveiro ME; Astorgues-Xerri L; Vazquez R; Frapolli R; Kwee I; Rinaldi A; Odore E; Rezai K; Bekradda M; Inghirami G; D'Incalci M; Noel K; Cvitkovic E; Raymond E; Bertoni F, 2016. OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.  Oncotarget 7(51):84675-84687

Rabi T; Catapano CV, 2016. Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells.  Tumour Biol 37(9):12455-12464

Albino D; Civenni G; Rossi S; Mitra A; Catapano CV; Carbone GM, 2016. The ETS factor ESE3/EHF represses IL-6 preventing STAT3 activation and expansion of the prostate cancer stem-like compartment.  Oncotarget 7(47):76756-76768

Gaudio E; Tarantelli C; Ponzoni M; Odore E; Rezai K; Bernasconi E; Cascione L; Rinaldi A; Stathis A; Riveiro E; Cvitkovic E; Zucca E; Bertoni F, 2016. Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.  Oncotarget 7(36):58142-58147

Restelli V; Vagni M; Arribas AJ; Bertoni F; Damia G; Carrassa L, 2016. Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation.  Br J Haematol.

Boi M; Gaudio E; Bonetti P; Kwee I; Bernasconi E; Tarantelli C; Rinaldi A; Testoni M; Cascione L; Ponzoni M; Mensah AA; Stathis A; Stussi G; Riveiro ME; Herait P; Inghirami G; Cvitkovic E; Zucca E; Bertoni F, 2015. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.  Clin Cancer Res 21(7):1628-38

Mensah AA; Kwee I; Gaudio E; Rinaldi A; Ponzoni M; Cascione L; Fossati G; Stathis A; Zucca E; Caprini G; Bertoni F, 2015. Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response.  Oncotarget 6(7):5059-71

Righi A; Gambarotti M; Benini S; Gamberi G; Cocchi S; Picci P; Bertoni F, 2015. MDM2 and CDK4 expression in periosteal osteosarcoma.  Hum Pathol 46(4):549-53

Testoni M; Zucca E; Young KH; Bertoni F, 2015. Genetic lesions in diffuse large B-cell lymphomas.  Ann Oncol 26(6):1069-80

Vesci L; Bernasconi E; Milazzo FM; De Santis R; Gaudio E; Kwee I; Rinaldi A; Pace S; Carollo V; Giannini G; Bertoni F, 2015. Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor.  Oncotarget 6(8):5735-48

Piva R; Deaglio S; Famà R; Buonincontri R; Scarfò I; Bruscaggin A; Mereu E; Serra S; Spina V; Brusa D; Garaffo G; Monti S; Dal Bo M; Marasca R; Arcaini L; Neri A; Gattei V; Paulli M; Tiacci E; Bertoni F; Pileri SA; Foà R; Inghirami G; Gaidano G; Rossi D, 2015. The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma.  Leukemia 29(2):503-7

Brambilla L; Genini D; Laurini E; Merulla J; Perez L; Fermeglia M; Carbone GM; Pricl S; Catapano CV, 2015. Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3).  Mol Oncol 9(6):1194-206

Testoni M; Chung EY; Priebe V; Bertoni F, 2015. The transcription factor ETS1 in lymphomas: friend or foe?  Leuk Lymphoma 56(7):1975-80

Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L, 2015. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.  Oncotarget 6(5):3394-408

Abate F; Todaro M; van der Krogt JA; Boi M; Landra I; Machiorlatti R; Tabbò F; Messana K; Abele C; Barreca A; Novero D; Gaudiano M; Aliberti S; Di Giacomo F; Tousseyn T; Lasorsa E; Crescenzo R; Bessone L; Ficarra E; Acquaviva A; Rinaldi A; Ponzoni M; Longo DL; Aime S; Cheng M; Ruggeri B; Piccaluga PP; Pileri S; Tiacci E; Falini B; Pera-Gresely B; Cerchietti L; Iqbal J; Chan WC; Shultz LD; Kwee I; Piva R; Wlodarska I; Rabadan R; Bertoni F; Inghirami G, 2015. A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.  Leukemia 29(6):1390-401

Iacovelli S; Hug E; Bennardo S; Duehren-von Minden M; Gobessi S; Rinaldi A; Suljagic M; Bilbao D; Bolasco G; Eckl-Dorna J; Niederberger V; Autore F; Sica S; Laurenti L; Wang H; Cornall RJ; Clarke SH; Croce CM; Bertoni F; Jumaa H; Efremov DG, 2015. Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL.  Blood 125(10):1578-88

Alajati A; Guccini I; Pinton S; Garcia-Escudero R; Bernasocchi T; Sarti M; Montani E; Rinaldi A; Montemurro F; Catapano C; Bertoni F; Alimonti A, 2015. Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer.  Cell Rep 11(4):564-76

Conconi A; Franceschetti S; Aprile von Hohenstaufen K; Margiotta-Casaluci G; Stathis A; Moccia AA; Bertoni F; Ramponi A; Mazzucchelli L; Cavalli F; Gaidano G; Zucca E, 2015. Histologic transformation in marginal zone lymphomas†.  Ann Oncol 26(11):2329-35

Restelli V; Chilà R; Lupi M; Rinaldi A; Kwee I; Bertoni F; Damia G; Carrassa L, 2015. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.  Oncotarget 6(35):37229-40

Ferretti E; Di Carlo E; Ognio E; Guarnotta C; Bertoni F; Corcione A; Prigione I; Fraternali-Orcioni G; Ribatti D; Ravetti JL; Ponzoni M; Tripodo C; Pistoia V, 2015. Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma.  Oncoimmunology 4(10):e1030560

Toso A; Di Mitri D; Alimonti A, 2015. Enhancing chemotherapy efficacy by reprogramming the senescence-associated secretory phenotype of prostate tumors: A way to reactivate the antitumor immunity.  Oncoimmunology 4(3):e994380

Conconi A; Lobetti-Bodoni C; Montoto S; Lopez-Guillermo A; Coutinho R; Matthews J; Franceschetti S; Bertoni F; Moccia A; Rancoita PM; Gribben J; Cavalli F; Gaidano G; Lister TA; Montserrat E; Ghielmini M; Zucca E, 2015. Life expectancy of young adults with follicular lymphoma.  Ann Oncol 26(11):2317-22

Di Mitri D; Toso A; Alimonti A, 2015. Tumor-infiltrating myeloid cells drive senescence evasion and chemoresistance in tumors.  Oncoimmunology 4(9):e988473

Kalathur M; Toso A; Chen J; Revandkar A; Danzer-Baltzer C; Guccini I; Alajati A; Sarti M; Pinton S; Brambilla L; Di Mitri D; Carbone G; Garcia-Escudero R; Padova A; Magnoni L; Tarditi A; Maccari L; Malusa F; Kalathur RK; A Pinna L; Cozza G; Ruzzene M; Delaleu N; Catapano CV; Frew IJ; Alimonti A, 2015. A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours.  Nat Commun 6:7227

Sgrignani J; Olsson S; Ekonomiuk D; Genini D; Krause R; Catapano CV; Cavalli A, 2015. Molecular Determinants for Unphosphorylated STAT3 Dimerization Determined by Integrative Modeling.  Biochemistry 54(35):5489-501

Bernasconi E; Gaudio E; Kwee I; Rinaldi A; Cascione L; Tarantelli C; Mensah AA; Stathis A; Zucca E; Vesci L; Giannini G; Bertoni F, 2015. The novel atypical retinoid ST5589 down-regulates Aurora Kinase A and has anti-tumour activity in lymphoma pre-clinical models.  Br J Haematol 171(3):378-86

Di Mitri D; Toso A; Alimonti A, 2015. Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy.  Clin Cancer Res 21(14):3108-12

Mian M; Kwee I; Rinaldi A; Ponzoni M; Bhagat G; Rossi D; Arcaini L; Gascoyne RD; Mollejo M; Baldini L; Thieblemont C; Gaidano G; Zucca E; Bertoni F, 2014. Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas.  Br J Haematol 164(6):896-9

Thieblemont C; Bertoni F; Copie-Bergman C; Ferreri AJ; Ponzoni M, 2014. Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type.  Semin Cancer Biol 24:33-42

Martínez N; Almaraz C; Vaqué JP; Varela I; Derdak S; Beltran S; Mollejo M; Campos-Martin Y; Agueda L; Rinaldi A; Kwee I; Gut M; Blanc J; Oscier D; Strefford JC; Martinez-Lopez J; Salar A; Sole F; Rodriguez-Peralto JL; Diez-Tascón C; García JF; Fraga M; Sebastián E; Alvés J; Menárguez J; González-Carreró J; Casado LF; Bayes M; Bertoni F; Gut I; Piris MA, 2014. Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation.  Leukemia 28(6):1334-40

Rocci A; Hofmeister CC; Geyer S; Stiff A; Gambella M; Cascione L; Guan J; Benson DM; Efebera YA; Talabere T; Dirisala V; Smith EM; Omedè P; Isaia G; De Luca L; Rossi D; Gentili S; Uccello G; Consiglio J; Ria R; Benevolo G; Bringhen S; Callea V; Weiss B; Ferro A; Magarotto V; Alder H; Byrd JC; Boccadoro M; Marcucci G; Palumbo A; Pichiorri F, 2014. Circulating miRNA markers show promise as new prognosticators for multiple myeloma.  Leukemia 28(9):1922-6

Liu X; Liu C; Catapano CV; Peng L; Zhou J; Rocchi P, 2014. Structurally flexible triethanolamine-core poly(amidoamine) dendrimers as effective nanovectors to deliver RNAi-based therapeutics.  Biotechnol Adv 32(4):844-52

Ok CY; Chen J; Xu-Monette ZY; Tzankov A; Manyam GC; Li L; Visco C; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Zhao X; Ponzoni M; Ferreri AJ; Bertoni F; Farnen JP; Møller MB; Piris MA; Winter JN; Medeiros LJ; Young KH, 2014. Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma.  Clin Cancer Res 20(19):5113-23

Zucca E; Bertoni F; Vannata B; Cavalli F, 2014. Emerging role of infectious etiologies in the pathogenesis of marginal zone B-cell lymphomas.  Clin Cancer Res 20(20):5207-16

Di Mitri D; Toso A; Chen JJ; Sarti M; Pinton S; Jost TR; D'Antuono R; Montani E; Garcia-Escudero R; Guccini I; Da Silva-Alvarez S; Collado M; Eisenberger M; Zhang Z; Catapano C; Grassi F; Alimonti A, 2014. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer.  Nature 515(7525):134-7

Zovko A; Viktorsson K; Hååg P; Kovalerchick D; Färnegårdh K; Alimonti A; Ilan M; Carmeli S; Lewensohn R, 2014. Marine sponge Cribrochalina vasculum compounds activate intrinsic apoptotic signaling and inhibit growth factor signaling cascades in non-small cell lung carcinoma.  Mol Cancer Ther 13(12):2941-54

Toso A; Revandkar A; Di Mitri D; Guccini I; Proietti M; Sarti M; Pinton S; Zhang J; Kalathur M; Civenni G; Jarrossay D; Montani E; Marini C; Garcia-Escudero R; Scanziani E; Grassi F; Pandolfi PP; Catapano CV; Alimonti A, 2014. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.  Cell Rep 9(1):75-89

Longoni N; Sarti M; Albino D; Civenni G; Malek A; Ortelli E; Pinton S; Mello-Grand M; Ostano P; D'Ambrosio G; Sessa F; Garcia-Escudero R; Thalmann GN; Chiorino G; Catapano CV; Carbone GM, 2013. ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-κB and drives prostate cancer progression.  Cancer Res 73(14):4533-47

Mian M; Rinaldi A; Mensah AA; Rossi D; Ladetto M; Forconi F; Marasca R; Uhr M; Stussi G; Kwee I; Cavalli F; Gaidano G; Zucca E; Bertoni F, 2013. Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH.  Ann Oncol 24(5):1378-84

Longoni N; Kunderfranco P; Pellini S; Albino D; Mello-Grand M; Pinton S; D'Ambrosio G; Sarti M; Sessa F; Chiorino G; Catapano CV; Carbone GM, 2013. Aberrant expression of the neuronal-specific protein DCDC2 promotes malignant phenotypes and is associated with prostate cancer progression.  Oncogene 32(18):2315-24, 2324.e1-4

Sarti M; Pinton S; Limoni C; Carbone GM; Pagani O; Cavalli F; Catapano CV, 2013. Differential expression of testin and survivin in breast cancer subtypes.  Oncol Rep 30(2):824-32

Lobetti-Bodoni C; Bertoni F; Stussi G; Cavalli F; Zucca E, 2013. The changing paradigm of chronic lymphocytic leukemia management.  Eur J Intern Med 24(5):401-10

Rinaldi A; Mensah AA; Kwee I; Forconi F; Orlandi EM; Lucioni M; Gattei V; Marasca R; Berger F; Cogliatti S; Cavalli F; Zucca E; Gaidano G; Rossi D; Bertoni F, 2013. Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma.  Br J Haematol 163(2):194-204

de Campos CP; Rancoita PM; Kwee I; Zucca E; Zaffalon M; Bertoni F, 2013. Discovering subgroups of patients from DNA copy number data using NMF on compacted matrices.  PLoS One 8(11):e79720

Boi M; Rinaldi A; Kwee I; Bonetti P; Todaro M; Tabbò F; Piva R; Rancoita PM; Matolcsy A; Timar B; Tousseyn T; Rodríguez-Pinilla SM; Piris MA; Beà S; Campo E; Bhagat G; Swerdlow SH; Rosenwald A; Ponzoni M; Young KH; Piccaluga PP; Dummer R; Pileri S; Zucca E; Inghirami G; Bertoni F, 2013. PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma.  Blood 122(15):2683-93

Chigrinova E; Rinaldi A; Kwee I; Rossi D; Rancoita PM; Strefford JC; Oscier D; Stamatopoulos K; Papadaki T; Berger F; Young KH; Murray F; Rosenquist R; Greiner TC; Chan WC; Orlandi EM; Lucioni M; Marasca R; Inghirami G; Ladetto M; Forconi F; Cogliatti S; Votavova H; Swerdlow SH; Stilgenbauer S; Piris MA; Matolcsy A; Spagnolo D; Nikitin E; Zamò A; Gattei V; Bhagat G; Ott G; Zucca E; Gaidano G; Bertoni F, 2013. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome.  Blood 122(15):2673-82

von Hohenstaufen KA; Conconi A; de Campos CP; Franceschetti S; Bertoni F; Margiotta Casaluci G; Stathis A; Ghielmini M; Stussi G; Cavalli F; Gaidano G; Zucca E, 2013. Prognostic impact of monocyte count at presentation in mantle cell lymphoma.  Br J Haematol 162(4):465-73

Publication list retrieved from NCBI using ImpactPubs


NOTE: this list was automatically generated by PubMed using the search string ‘(Bertoni F OR Catapano CV OR Catapano C OR Alimonti A OR Carbone GM OR Theurillat JP OR Rossi D) AND (IOSI[AD] OR IOR[AD]) “last 3 years”[DP]’